Lipopharma currently investigates the therapeutic applications of new compounds designed on the basis of our innovative Membrane-Lipid Therapy (MLT) know-how.
LP205A1 is a polyunsaturated fatty acid derivative currently being investigated as a potential therapeutic candidate for potential indications in neurodegeneration, metabolic or cardiovascular diseases.
LP10218 and LP20104 are omega-6 PUFA synthetic derivatives with significant antitumor activity. Cancer applications for this compounds have been out-licensed to Ability Pharmaceuticals (former AB-Therapeutics)
LP30171 is a new MLT-based fatty acid derivative, designed by Lipopharma's scientists, currently being investigated as a potential treatment for cancer and metabolic disorders.